Diabetic nephropathy medical therapy: Difference between revisions

Jump to navigation Jump to search
Aarti Narayan (talk | contribs)
Luke Rusowicz-Orazem (talk | contribs)
No edit summary
Line 26: Line 26:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Kidney diseases]]
[[Category:Pediatrics]]
[[Category:Angiology]]
[[Category:Endocrinology]]
[[Category:Diabetes]]
[[Category:Nephrology]]
[[Category:Disease]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 19:39, 25 July 2016

Diabetic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic nephropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy medical therapy

CDC on Diabetic nephropathy medical therapy

Diabetic nephropathy medical therapy in the news

Blogs on Diabetic nephropathy medical therapy

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The goals of treatment are to slow the progression of kidney damage and control related complications. The main treatment, once proteinuria is established, is ACE inhibitor drugs, which usually reduces glomerular hypertension, proteinuria levels, systemic hypertension and slows the progression of diabetic nephropathy.

Medical Therapy

Drug interaction

Patients with diabetic nephropathy should avoid taking the following drugs:

References

Template:WH Template:WS